IBRX - ImmunityBio announces $320M investment by Oberland Capital
2024-01-02 06:11:57 ET
More on ImmunityBio
- ImmunityBio: Approval Likely Priced In, Yielding Mostly Risk For Would-Be Buyers
- ImmunityBio: On The Verge, But With Many Questions Remaining
- ImmunityBio: The CRL Makes It Riskier Than Ever
- ImmunityBio gains as bladder cancer therapy undergoes FDA review
- ImmunityBio extends gains on surging volumes after regulatory update
For further details see:
ImmunityBio announces $320M investment by Oberland Capital